Accelerate Diagnostics Inc. (NASDAQ:AXDX) shares were up 3.8% during mid-day trading on Monday . The stock traded as high as $20.72 and last traded at $20.39, with a volume of 82,028 shares changing hands. The stock had previously closed at $19.65.

Several research analysts have recently issued reports on AXDX shares. BTIG Research reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Accelerate Diagnostics in a research note on Wednesday, June 15th. Piper Jaffray Cos. reissued a “buy” rating on shares of Accelerate Diagnostics in a research report on Monday, April 11th. Finally, Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $22.67.

The stock’s market capitalization is $1.03 billion. The firm’s 50 day moving average price is $17.44 and its 200-day moving average price is $14.15.

In other Accelerate Diagnostics news, Director Jack W. Schuler purchased 11,511 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was purchased at an average price of $11.91 per share, for a total transaction of $137,096.01. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jack W. Schuler purchased 88,316 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were acquired at an average price of $14.69 per share, with a total value of $1,297,362.04. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.